NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

亞伯氏症候群 - 流行病學預測 2028年

Alport Syndrome - Epidemiology Forecast - 2028

出版商 DelveInsight Business Research LLP 商品編碼 915397
出版日期 按訂單生產 內容資訊 英文 60 Pages
商品交期: 2-10個工作天內
價格
亞伯氏症候群 - 流行病學預測 2028年 Alport Syndrome - Epidemiology Forecast - 2028
出版日期: 按訂單生產內容資訊: 英文 60 Pages
簡介

新興10個國家(土耳其、沙烏地阿拉伯、阿拉伯聯合大公國、墨西哥、哥倫比亞、巴西、阿根廷、俄羅斯、中國、台灣)的亞伯氏症候群2017年的患病數估算為18萬7,718人。

本報告提供新興10個國家(土耳其、沙烏地阿拉伯、阿拉伯聯合大公國、墨西哥、哥倫比亞、巴西、阿根廷、俄羅斯、中國、台灣)的亞伯氏症候群市場調查,疾病概要和現行的治療方法,已上市治療藥的簡介,未滿足需求,整體及各國的市場趨勢,流行病學的預測,市患病數的變化與預測,市場成長要素及障礙等資訊總括性彙整。

目錄

第1章 重要的洞察

第2章 亞伯氏症候群:流行病學概要

  • 亞伯氏症候群的患病數(實在數值)
  • 亞伯氏症候群的患病數(預測值)

第3章 亞伯氏症候群:疾病背景和概要

  • 簡介
  • 原因和風險因素
  • 遺傳模式
  • 徵兆與症狀
  • 臨床症狀
    • 腎臟症狀
    • 聽覺症狀
    • 眼科症狀
  • 病理生理學
  • 診斷方法

第4章 治療

  • 現行的治療方法
  • 未來的治療方法
  • 治療演算法

第5章 未滿足需求

第6章 治療貢獻的組織

第7章 關鍵意見領袖的意見

第8章 Key Cross Competition

第9章 已上市治療藥

  • Bardoxolone Methyl:Reata Pharmaceuticals
    • 產品說明
    • 臨床開發
    • 其他開發活動
    • 產品簡介
  • RG 012 / SAR339375:Sanofi

第10章 病例報告

第11章 流行病學和患者人口

  • 主要調查結果

第12章 新興10個國家的亞伯氏症候群的總患病數

第13章 亞伯氏症候群的流行病學:各國

  • 假設和根據
  • 中南美
    • 阿根廷
    • 巴西
    • 哥倫比亞
    • 墨西哥
  • 歐洲、中東
    • 俄羅斯
    • 沙烏地阿拉伯
    • 土耳其
    • 阿拉伯聯合大公國
  • 亞洲
    • 中國
    • 台灣

第14章 市場成長要素

第15章 市場障礙

第16章 附錄

第17章 DelveInsight的服務內容

第18章 免責聲明

第19章 關於DelveInsight

目錄
Product Code: DIEI0387

DelveInsight's "Alport Syndrome -Epidemiology Forecast-2028" report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Alport syndrome in Turkey, Russia, Colombia, Brazil, Argentina, Mexico, Saudi Arabia, UAE, Taiwan, and China.

Geography Covered

  • Turkey
  • Russia
  • Colombia
  • Brazil
  • Argentina
  • Mexico
  • Saudi Arabia
  • UAE
  • Taiwan
  • China

Study Period: 2017-2028

Alport Syndrome - Epidemiology

The Alport syndrome epidemiology division provides the insights about historical and current patient pool and forecasted trend for all ten emerging market. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the total disease prevalence, diagnosed cases, treatable cases and prevalence based on clinical types and clinical manifestations in Turkey, Russia, Colombia, Brazil, Argentina, Mexico, Saudi Arabia, UAE, Taiwan, and China.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases, total diagnosed cases and total treatable cases) scenario of Alport syndrome in the ten emerging markets, i.e., Turkey, Russia, Colombia, Brazil, Argentina, Mexico, Saudi Arabia, UAE, Taiwan, and China from 2017-2028.

According to DelveInsight, total prevalent population of Alport syndrome in ten emerging markets was found to be 187,718 in 2017. 

Alport syndrome Report Insights

  • The report covers detailed overview of Alport syndrome explaining its causes, symptoms, and pathophysiology, diagnosis and treatment patterns.
  • The report provides the insight about the historical and forecasted patient pool for ten emerging market i.e. Turkey, Russia, Colombia, Brazil, Argentina, Mexico, Saudi Arabia, UAE, Taiwan, and China.
  • The Report highlights the unmet needs of Alport syndrome.
  • The Report helps to recognize the growth opportunities in the ten emerging markets with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology by total prevalent population, diagnosed cases, treatable cases and clinical types and clinical manifestations specific prevalent population in ten emerging market.

Alport syndrome Report Key Strengths

  • 10 Year Forecast
  • 10 emerging market Coverage
  • Prevalent cases
  • Diagnosed cases
  • Treatable cases
  • Clinical types specific prevalent population
  • Clinical manifestations specific prevalent population

Alport syndrome Report Assessment

  • Patient Segmentation
  • Disease Risk & Burden
  • Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Alport Syndrome: Epidemiology Overview at a Glance

  • 2.1. Total Prevalent Population of Alport Syndrome in 2017
  • 2.2. Total Prevalent Population of Alport Syndrome in 2028

3. Alport Syndrome: Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Causes and Risk Factors
  • 3.3. Inheritance Pattern
  • 3.4. Signs and Symptoms
  • 3.5. Clinical Manifestations
    • 3.5.1. Renal Manifestations
    • 3.5.2. Audiological Manifestations
    • 3.5.3. Ophthalmological Manifestations
  • 3.6. Pathophysiology
  • 3.7. Diagnostic Approach

4. Treatment

  • 4.1. Current treatment for Alport Syndrome
  • 4.2. Future treatment for Alport Syndrome
  • 4.3. Treatment Algorithm

5. Unmet Needs

6. Organizations contributing toward Alport Syndrome

7. KOL's Views: Alport Syndrome

8. Key Cross Competitors

9. Marketed Drugs

  • 9.1. Bardoxolone Methyl: Reata Pharmaceuticals
    • 9.1.1. Product Description
    • 9.1.2. Clinical Development
    • 9.1.3. Other Development Activities
    • 9.1.4. Product Profile
  • 9.2. RG 012/ SAR339375: Sanofi
    • 9.2.1. Product Description
    • 9.2.2. Clinical Development
    • 9.2.3. Other Development Activities
    • 9.2.4. Product Profile

10. Case Reports

  • 10.1. A Novel COL4A3 Mutation Causes Autosomal-Recessive Alport Syndrome in a Large Turkish Family
  • 10.2. Alport-like glomerular changes in a patient with nephrotic syndrome: report of a case
  • 10.3. Alport Syndrome with Recurrent Herpes Simplex Virus Keratitis
  • 10.4. Russian Family with X-linked Alport Syndrome and Cardiovascular Abnormalities
  • 10.5. An overlap of Alport syndrome and rheumatoid arthritis in a patient and literature review
  • 10.6. Macular Hole Surgery in Alport Syndrome
  • 10.7. Female Patient with Alport Syndrome and Concomitant Membranous Nephropathy: Susceptibility or Association of Two Diseases?
  • 10.8. Podocyturia: A Clue for the Rational Use of Amiloride in Alport Renal Disease
  • 10.9. Nephropathies with a pattern of structural alterations of the glomerular basement membrane: Case study

11. Epidemiology and Patient Population

  • 11.1. Key Findings

12. Emerging Markets Total Prevalent Population of Alport Syndrome

13. Country Wise-Epidemiology of Alport Syndrome

  • 13.1. Assumptions and Rationale
  • 13.2. Latin America
    • 13.2.1. Argentina
    • 13.2.2. Brazil
    • 13.2.3. Colombia
    • 13.2.4. Mexico
  • 13.3. Middle East and Europe
    • 13.3.1. Russia
    • 13.3.2. Saudi Arabia
    • 13.3.3. Turkey
    • 13.3.4. United Arab Emirates (UAE)
  • 13.4. Asia
    • 13.4.1. China
    • 13.4.2. Taiwan

14. Market Drivers

15. Market Barriers

16. Appendix

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

List of Tables

  • Table 1: List of drugs for the treatment of Alport syndrome
  • Table 2: Organizations contributing toward Alport Syndrome
  • Table 3: Key Cross Competitors
  • Table 4: Bardoxolone Methyl, Clinical Trial Description, 2019
  • Table 5: Bardoxolone Methyl, Safety and Efficacy Description
  • Table 6: Bardoxolone Methyl, Drug Profile
  • Table 7: RG 012, Clinical Trial Description, 2019
  • Table 8: RG012, Preclinical Results
  • Table 9: RG 012, Drug Profile
  • Table 10: Total Prevalent Patient Population of Alport Syndrome in 10 emerging markets (2017-2028)
  • Table 11: Total Prevalent Population of Alport Syndrome in Argentina (2017-2028)
  • Table 12: Total Prevalent Population Based on Clinical Types of Alport Syndrome in Argentina (2017-2028)
  • Table 13: Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in Argentina (2017-2028)
  • : Diagnosed cases of Alport Syndrome in Argentina (2017-2028)
  • Table 14: Treatable cases of Alport Syndrome in Argentina (2017-2028)
  • Table 15: Total Prevalent Population of Alport Syndrome in Brazil (2017-2028)
  • Table 16: Total Prevalent Population Based on Clinical Types of Alport Syndrome in Brazil (2017-2028)
  • Table 17 : Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in Brazil (2017-2028)
  • Table 18: Diagnosed cases of Alport Syndrome in Brazil (2017-2028)
  • Table 19: Treatable cases of Alport Syndrome in Brazil (2017-2028)
  • Table 20: Total Prevalent Population of Alport Syndrome in Colombia (2017-2028)
  • Table 21: Total Prevalent Population Based on Clinical Types of Alport Syndrome in Colombia (2017-2028)
  • Table 22: Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in Colombia (2017-2028)
  • Table 23: Diagnosed cases of Alport Syndrome in Colombia (2017-2028)
  • : Treatable cases of Alport Syndrome in Colombia (2017-2028)
  • Table 24: Total Prevalent Population of Alport Syndrome in Mexico (2017-2028)
  • Table 25: Total Prevalent Population Based on Clinical Types of Alport Syndrome in Mexico (2017-2028)
  • Table 26: Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in Mexico (2017-2028)
  • Table 27: Diagnosed cases of Alport Syndrome in Mexico (2017-2028)
  • Table 28: Treatable cases of Alport Syndrome in Mexico (2017-2028)
  • Table 29: Total Prevalent Population of Alport Syndrome in Russia (2017-2028)
  • Table 30: Total Prevalent Population Based on Clinical Types of Alport Syndrome in Russia (2017-2028)
  • Table 31: Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in Russia (2017-2028)
  • Table 32: Diagnosed cases of Alport Syndrome in Russia (2017-2028)
  • Table 33: Treatable cases of Alport Syndrome in Russia (2017-2028)
  • Table 34: Total Prevalent Population of Alport Syndrome in Saudi Arabia (2017-2028)
  • Table 35: Total Prevalent Population Based on Clinical Types of Alport Syndrome in Saudi Arabia (2017-2028)
  • Table 36: Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in Saudi Arabia (2017-2028)
  • Table 37: Diagnosed cases of Alport Syndrome in Saudi Arabia (2017-2028)
  • Table 38: Treatable cases of Alport Syndrome in Saudi Arabia (2017-2028)
  • : Total Prevalent Population of Alport Syndrome in Turkey (2017-2028)
  • Table 39: Total Prevalent Population Based on Clinical Types of Alport Syndrome in Turkey (2017-2028)
  • Table 40: Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in Turkey (2017-2028)
  • Table 41: Diagnosed cases of Alport Syndrome in Turkey (2017-2028)
  • Table 42: Treatable cases of Alport Syndrome in Turkey (2017-2028)
  • Table 43: Total Prevalent Population of Alport Syndrome in UAE (2017-2028)
  • Table 44: Total Prevalent Population Based on Clinical Types of Alport Syndrome in UAE (2017-2028)
  • Table 45: Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in UAE (2017-2028)
  • Table 46: Diagnosed cases of Alport Syndrome in UAE (2017-2028)
  • Table 47: Treatable cases of Alport Syndrome in UAE (2017-2028)
  • Table 48: Total Prevalent Population of Alport Syndrome in China (2017-2028)
  • Table 49: Total Prevalent Population Based on Clinical Types of Alport Syndrome in China (2017-2028)
  • Table 50: Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in China (2017-2028)
  • Table 51: Diagnosed cases of Alport Syndrome in China (2017-2028)C
  • Table 52: Treatable cases of Alport Syndrome in China (2017-2028)
  • Table 53: Total Prevalent Population of Alport Syndrome in Taiwan (2017-2028)
  • Table 54: Total Prevalent Population Based on Clinical Types of Alport Syndrome in Taiwan (2017-2028)
  • Table 55: Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in Taiwan (2017-2028)
  • Table 56: Diagnosed cases of Alport Syndrome in Taiwan (2017-2028)
  • Table 57: Treatable cases of Alport Syndrome in Taiwan (2017-2028)

List of Figures

  • Figure 1 Total Prevalent Population of Alport Syndrome in the emerging markets (2017)
  • Figure 2 Total Prevalent Population of Alport Syndrome in the emerging markets (2028)
  • Figure 3 A frozen human kidney section stained in red for COL4A4, representing the α-3 α-4 α-5(IV) network
  • Figure 4 XLAS inheritance pattern (affected father)
  • Figure 5 XLAS inheritance pattern (affected mother)
  • Figure 6 ARAS inheritance pattern
  • Figure 7 ADAS inheritance pattern
  • Figure 8 Clinical manifestations
  • Figure 9 Clinical presentation in Alport syndrome and the potential effect of treatment
  • Figure 10 Fundus examination of the eye demonstrating peri-macular flecks
  • Figure 11 Vesicle-like lesions in PPCD
  • Figure 12 Normal and Alport glomerular filtration barriers
  • Figure 13 Potential mechanisms underlying chronic renal disease occurring in Alport syndrome
  • Figure 14 Indications for genetic testing in Alport syndrome
  • Figure 15 An approach to diagnose Alport syndrome
  • Figure 16 Medications for Alport Syndrome
  • Figure 17 Therapeutic targets in Alport syndrome
  • Figure 18 Treatment Algorithm for Alport Syndrome
  • Figure 19 Unmet Needs of Alport Syndrome
  • Figure 20 Mechanism of action of Bardoxolone Methyl
  • Figure 21 Study Design: CARDINAL
  • Figure 22 Mechanism of action of RG 012
  • Figure 23 Total Prevalent Population of Alport Syndrome in 10 emerging markets (2017-2028)
  • Figure 24 Total Prevalent Population of Alport Syndrome in Argentina (2017-2028)
  • Figure 25 Total Prevalent Population Based on Clinical Types of Alport Syndrome in Argentina (2017-2028)
  • Figure 26 Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in Argentina (2017-2028)
  • Figure 27 Diagnosed Cases of Alport Syndrome in Argentina (2017-2028)
  • Figure 28 Treatable Cases of Alport Syndrome in Argentina (2017-2028)
  • Figure 29 Total Prevalent Population of Alport Syndrome in Brazil (2017-2028)
  • Figure 30 Total Prevalent Population Based on Clinical Types of Alport Syndrome in Brazil (2017-2028)
  • Figure 31 Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in Brazil (2017-2028)
  • Figure 32 Diagnosed Cases of Alport Syndrome in Brazil (2017-2028)
  • Figure 33 Treatable Cases of Alport Syndrome in Brazil (2017-2028)
  • Figure 34 Total Prevalent Population of Alport Syndrome in Colombia (2017-2028)
  • Figure 35 Total Prevalent Population Based on Clinical Types of Alport Syndrome in Colombia (2017-2028)
  • Figure 36 Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in Colombia (2017-2028)
  • Figure 37 Diagnosed Cases of Alport Syndrome in Colombia (2017-2028)
  • Figure 38 Treatable Cases of Alport Syndrome in Colombia (2017-2028)
  • Figure 39 Total Prevalent Population of Alport Syndrome in Mexico (2017-2028)
  • Figure 40 Total Prevalent Population Based on Clinical Types of Alport Syndrome in Mexico (2017-2028)
  • Figure 41 Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in Mexico (2017-2028)
  • Figure 42 Diagnosed Cases of Alport Syndrome in Mexico (2017-2028)
  • Figure 43 Treatable Cases of Alport Syndrome in Mexico (2017-2028)
  • Figure 44 Total Prevalent Patient Population of Alport Syndrome in Russia (2017-2028)
  • Figure 45 Total Prevalent Patient Population Based on Clinical Types of Alport Syndrome in Russia (2017-2028)
  • Figure 46 Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in Russia (2017-2028)
  • Figure 47 Diagnosed Cases of Alport Syndrome in Russia (2017-2028)
  • Figure 48 Treatable Cases of Alport Syndrome in Russia (2017-2028)
  • Figure 49 Total Prevalent Population of Alport Syndrome in Saudi Arabia (2017-2028)
  • Figure 50 Total Prevalent Population Based on Clinical Types of Alport Syndrome in Saudi Arabia (2017-2028)
  • Figure 51 Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in Saudi Arabia (2017-2028)
  • Figure 52 Diagnosed Cases of Alport Syndrome in Saudi Arabia (2017-2028)
  • Figure 53 Treatable Cases of Alport Syndrome in Saudi Arabia (2017-2028)
  • Figure 54 Total Prevalent Population of Alport Syndrome in Turkey (2017-2028)
  • Figure 55 Total Prevalent Population Based on Clinical Types of Alport Syndrome in Turkey (2017-2028)
  • Figure 56 Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in Turkey (2017-2028)
  • Figure 57 Diagnosed Cases of Alport Syndrome in Turkey (2017-2028)
  • Figure 58 Treatable Cases of Alport Syndrome in Turkey (2017-2028)
  • Figure 59 Total Prevalent Population of Alport Syndrome in UAE (2017-2028)
  • Figure 60 Total Prevalent Population Based on Clinical Types of Alport Syndrome in the UAE (2017-2028)
  • Figure 61 Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in the UAE (2017-2028)
  • Figure 62 Diagnosed Cases of Alport Syndrome in the UAE (2017-2028)
  • Figure 63 Treatable Cases of Alport Syndrome in the UAE (2017-2028)
  • Figure 64 Total Prevalent Population of Alport Syndrome in China (2017-2028)
  • Figure 65 Total Prevalent Population Based on Clinical Types of Alport Syndrome in China (2017-2028)
  • Figure 66
  • Figure 67
  • Figure 68
  • Figure 69
  • Figure 70
  • Figure 71
  • Figure 72
  • Figure 73
  • Figure 74
  • Figure 75 Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in China (2017-2028)
  • Diagnosed Cases of Alport Syndrome in China (2017-2028)
  • Treatable Cases of Alport Syndrome in China (2017-2028)
  • Total Prevalent Population of Alport Syndrome in Taiwan (2017-2028)
  • Total Prevalent Population Based on Clinical Types of Alport Syndrome in Taiwan (2017-2028)
  • Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in Taiwan (2017-2028)
  • Diagnosed Cases of Alport Syndrome in Taiwan (2017-2028)
  • Treatable Cases of Alport Syndrome in Taiwan (2017-2028)
  • Market Drivers
  • Market Barriers